(BTCY) Continues To Heat Up, Could Be Entering Breakout Mode As A New Day High Was Just Reached

I'm going to keep this short because you need to get your eyes on BTCY quickly. (BTCY) Continues To Heat Up, Could Be Entering Breakout Mode As A New Day High Was Just Reached September 15th FierceAnalyst Reader, I'm going to keep this short because you need to get your eyes on BTCY quickly. BTCY has now hit a new day high of $3.54+ while [Barchart]( has now upgraded this profile to a "72% BUY" based on overall technical indicators. Furthermore, the website is now reporting BTCY to have 11 triggered technical indicators through the short, medium, and long term. Could the potential resistance around BTCY's [50-Day Simple Moving Average be breaking down?]( Like I said, if that happens, things could get crazy. Plus, check out the major company news BTCY dropped this week: [Biotricity Unveils "Biokit" with 3 Personal Medical Devices to Expand into Cardiac Disease Management]( Get BTCY at the top of your watch-list ASAP. ----- It's now Wednesday morning and the bell has just popped off. I've been tracking a Nasdaq MedTech idea that's currently flying under Wall Street's radar and you gotta get it on your radar ASAP. Goldman Sachs claims that wearables and digital health could save the U.S. healthcare industry up to approximately $300Bn.(1) Furthermore, the total connected health market is growing at an estimated 27.6% CAGR and could potentially reach a staggering $188Bn by 2024.(2) Another report from AllTheResearch claims that the global IoMT market could reach approximately $254.23Bn by 2026.(3) In other words: Med + Tech = Undisputable Growth Potential In The Immediate Future Through developing innovative devices that track, analyze, and report, all while cutting costs, this one company could significantly impact the entire healthcare industry. For Wednesday, September 15th, there is only one Nasdaq profile to have on your radar: *Biotricty, Inc. (BTCY)* Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. Its Foundational Product, Bioflux, is Targeting a Growing and Underserved Market The company’s first and primary solution, Bioflux, addresses the growing and underserved Mobile Cardiac Telemetry (MCT) market. Bioflux is a high-precision, single-unit MCT device providing real-time monitoring and transmission of ECG information from ambulatory patients. This entire system is a complete solution for remote cardiac monitoring that merges seamlessly with physicians’ existing platforms and workflows to better detect, diagnose, and monitor. For medical practitioners, this solution looks to be technologically superior and more financially attractive too. Clinicians designed the Bioflux online portal for clinicians. After all, the prime features of the product were built after speaking with numerous healthcare professionals and seeing what their most requested features were. And right now, BTCY has 5 potential catalysts that could spark a possible breakout. Here's what you need to know... Your No. 1 Potential BTCY Breakout Catalyst - Huge Revenue Growth YoY Biotricity Reports 290% Revenue Growth Year Over Year in Record First Quarter REDWOOD CITY, CA / ACCESSWIRE / August 16, 2021 /Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to provide financial results for its fiscal 2022 first quarter, which ended June 30, 2021. Full financial results will be posted on EDGAR later today. Biotricity's Q1 results maintain a trend of both sequential and year over year (YoY) growth, with revenue once again setting a new quarterly record. For Q1 Fiscal 2022, management is noting the following highlights: - Q1 revenue of $1.76Mn represented the 9th consecutive quarter of triple digit YoY growth - Quarterly revenue increased 290% when comparing the first quarter of fiscal 2022 to the corresponding quarter of fiscal 2021, showing continued acceleration over the 227% growth in Q4/2021, 162% growth in Q3/2021, and 115% growth in Q2/2021 - Quarterly sequential revenue increased 49% compared to 19% posted in the prior quarter, a significant acceleration bolstered by consistent month-over-month sequential growth - The Company nearly tripled sales with a smaller corresponding increase in Operating Expenses, which rose only 17% to $4.2Mn for Q1 FY22 compared to $3.6Mn in the prior year "Continuous quarter over quarter revenue growth is a testament to our continued effort to expand our salesforce and footprint," stated Dr. Waqaas Al-Siddiq. "Our Technology as a Service (TaaS) model and highly competitive solution is attracting an increasing number of cardiologists to the Biotricity brand. We are still waiting to receive approval from the FDA for our Biotres holter product, which will give us a major new product to sell to our existing customers." [...] [Read the full article here.]( ----- Your No. 2 Potential BTCY Breakout Catalyst - Analysts Provide Major Price Targets Back on July 1st, two different analysts provided $7.00 price targets according to [MarketBeat's website.]( Check them out: On top of those 2, Maxim Group analyst, Allen Klee, tagged BTCY with a $6.00 target over the summer. Here's some quick notes from a [Benzinga article]( regarding Klee's report: - The Biotricity Thesis: The company has been generating triple-digit year-over-year revenue growth and could continue doing so through fiscal 2024, Klee said in the initiation note. - Biotricity’s first product, Bioflux, is a “best-in-class offering in terms of data quality, built-in connectivity, and upgraded software to improve automation and results,” the analyst noted. - He added that the company plans to launch a new product every 12 to 18 months, in order to expand the ecosystem for cardiologists. - “In June, Bioheart will go live with a direct-to-consumer, best-in-class heart monitoring product” and its next product with the FDA is Biotres, focused on monitoring less risky patients, Klee wrote. - He estimates the total addressable market at $1Bn for Bioflux and at $2Bn for Biotres. - “We project annual revenue growth of over 100% through FY24, and gross margin to improve from close to 50% today, to 75%+ when at scale,” the analyst said. ----- Your No. 3 Potential BTCY Breakout Catalyst - Bullish Technicals + Trading From Potential Support At close on Tuesday, [Barchart]( was report BTCY to have multiple bullish technical indicators. Here's a quick list of the triggered technicals: Short Term Indicators - 20 - 100 Day MACD Oscillator - 20 - 200 Day MACD Oscillator Medium Term Indicators - 50 - 100 Day MACD Oscillator - 50 - 150 Day MACD Oscillator - 50 - 200 Day MACD Oscillator Long Term Indicators - 100 Day Moving Average - 150 Day Moving Average - 200 Day Moving Average - 100 - 200 Day MACD Oscillator On top of that, BTCY is trading above multiple lines of potential support according to [Barchart](. Here they are: - 5-Day Exponential Moving Average (EMA) - 13-Day EMA - 100-Day Simple Moving Average (SMA) - 200-Day SMA Could all this potential support and bullish technicals fuel a potential vertical shot up the charts? ----- Your No. 4 Potential BTCY Breakout Catalyst - Completing Recent Nasdaq Listing Biotricity Completes Nasdaq Listing REDWOOD CITY, CA / ACCESSWIRE / August 30, 2021 / Biotricity, Inc.(NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the closing of an underwritten public offering of 5Mn shares of common stock of the Company for total gross proceeds to the Company of approximately $15Mn. The offering was priced at $3.00 per share. In addition, the Company has granted the underwriter of the offering a 30-day option to purchase an additional 750k shares of common stock at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital, potential acquisitions, and other business opportunities. In connection with the offering the Company's common stock, on August 26, 2021 the Company common st-ock was listed on the Nasdaq Capital Market under the symbol "BTCY." [...] [Read the full article here.]( ----- Your No. 5 Potential BTCY Breakout Catalyst - Annual Revenue Reporting Through The Roof Biotricity Reports Record Quarterly and Annual Revenue for Fiscal 2021 REDWOOD CITY, CA / ACCESSWIRE / June 15, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to provide unaudited, preliminary financial results for its fiscal 2021 fourth quarter and fiscal year, which ended March 31, 2021. Full financial results will be posted on EDGAR by June 31, 2021. Biotricity's Q4 and annual results continued a trend of both sequential and year over year (YoY) revenue growth, with revenue setting a new quarterly record in the fiscal fourth quarter. For fiscal 2021, management is noting the following highlights: - Q4 revenue of $1.2Mn represented the 8th consecutive quarter of triple digit YoY growth - Quarterly revenue increased 227%, showing significant acceleration over the 162% increase posted in the prior quarter - Quarterly sequential revenue increased 19%, bolstered by a long-term trend of month-over-month sequential growth - Net loss attributable to common stockholders amounted to $16.2Mn, or 43.1 cents per share - Annual revenue reached $3.4Mn, a 139% increase over fiscal 2020 "Our growth this quarter was even stronger than last quarter, which is exciting to see, as this is purely organic and the impact of our new products has not yet begun," stated Waqaas Al-Siddiq, CEO of Biotricity. "We are in that sweet spot of our revenue cycle where we are posting strong monthly, quarterly and annual growth, with visibility out several years. As we enter a period of expected revenue acceleration, our model is proving to be highly predictable based on our consistent ability to win accounts throughout the U.S. We expect to easily beat Q4 revenue in our current quarter ending June 30, 2021 and are targeting triple digit revenue growth for fiscal 2022." [...] [Read the full article here.]( ----- BTCY Recap: 5 Potential Breakout Catalysts For This Nasdaq Profile No. 1 - Huge Revenue Growth YoY No. 2 - Analysts Provide Major Price Targets No. 3 - Bullish Technicals + Trading From Potential Support No. 4 - Completing Recent Nasdaq Listing No. 5 - Annual Revenue Reporting Through The Roof Coverage is officially initiated on BTCY. When you have time later, do this: If there are more updates today, I'll get them out to you quickly. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer  [Source 1]( [Source 2]( [Source 3]( [Company Website]( Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net